Abstract
In patients with chronic kidney disease (CKD) or those undergoing hemodialysis, pathological calcific deposition known as ectopic calcification occurs in soft tissue, resulting in a life-threatening disorder. A potent and effective inhibitor of ectopic calcification is eagerly expected. In the current study, the effects of FYB-931, a novel bisphosphonate compound synthesized for the prevention of ectopic calcification, were compared with those of etidronate using both in vitro and in vivo models. In vitro, FYB-931 inhibited calcification of human aortic smooth muscle cells induced by high phosphate medium in a concentration-dependent manner, and the effect was slightly more potent than that of etidronate. In vivo, rats were administered with three subcutaneous injections of vitamin D3 to induce vascular calcification, and were given FYB-931 (1.5, 5, or 10 mg/kg) or etidronate (9, 30, or 60 mg/kg) orally once daily for 14 days. The increased aortic phosphorus content as an index of vascular calcification was inhibited by both FYB-931 and etidronate in a dose-dependent manner; however, FYB-931 was 10 times more potent than etidronate. FYB-931 inhibited serum tartrate-resistant acid phosphatase (TRACP) activity as a bone resorption marker 5.2 times more potently than etidronate. FYB-931, but not etidronate, significantly decreased serum phosphorus levels. The preferential inhibition of aortic calcification by FYB-931 suggested that possible additional effect including a decline in serum phosphorus may lead to an advantage in terms of its efficacy.
Similar content being viewed by others
References
Fang Y, Ginsberg C, Sugatani T, Monier-Faugere MC, Malluche H, Hruska KA (2014) Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int 85:142–150
Giachelli CM (2004) Vascular calcification mechanisms. J Am Soc Nephrol 15:2959–2964
Giachelli CM (1999) Ectopic calcification: gathering hard facts about soft tissue mineralization. Am J Pathol 154:671–675
Matsuoka M, Iseki K, Tamashiro M, Fujimoto N, Higa N, Touma T, Takishita S (2004) Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 8:54–58
Yiu AJ, Callaghan D, Sultana R, Bandyopadhyay BC (2015) Vascular calcification and stone disease: a new look towards the mechanism. J Cardiovasc Dev Dis 2:141–164
Karwowski W, Naumnik B, Szczepański M, Myśliwiec M (2012) The mechanism of vascular calcification: a systematic review. Med Sci Monit 18:1–11
Wu M, Rementer C, Giachelli CM (2013) Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int 93:365–373
Hashiba H, Aizawa S, Tamura K, Shigemastu T, Kogo H (2004) Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. Ther Apher Dial 8:241–247
Hashiba H, Aizawa S, Tamura K, Kogo H (2006) Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects. Ther Apher Dial 10:59–64
Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, Aoki T, Nihei H (2004) Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 44:680–688
Koshiyama H, Nakamura Y, Tanaka S, Minamikawa J (2000) Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes. J Clin Endocrinol Metab 85:2793–2796
Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268
Price PA, Faus SA, Williamson MK (2001) Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21:817–824
Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG (2010) Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 56:57–68
Tankó LB, Qin G, Alexandersen P, Bagger YZ, Christiansen C (2005) Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporos Int 16:184–190
Zavaczki E, Jeney V, Agarwal A, Zarjou A, Oros M, Katkó M, Varga Z, Balla G, Balla J (2011) Hydrogen sulfide inhibits the calcification and osteoblastic differentiation of vascular smooth muscle cells. Kidney Int 80:731–739
Ferrer MD, Pérez MM, Cànaves MM, Buades JM, Salcedo C, Perelló J (2017) A novel pharmacodynamic assay to evaluate the effects of crystallization inhibitors on calcium phosphate crystallization in human plasma. Sci Rep 7:6858
Ziegler SG, Ferreira CR, MacFarlane EG, Riddle RC, Tomlinson RE, Chew EY, Martin L, Ma CT, Sergienko E, Pinkerton AB, Millán JL, Gahl WA, Dietz HC (2017) Ectopic calcification in pseudoxanthoma elasticum responds to inhibition of tissue-nonspecific alkaline phosphatase. Sci Transl Med 9:1–25
Marma MS, Xia Z, Stewart C, Coxon F, Dunford JE, Baron R, Kashemirov BA, Ebetino FH, Triffitt JT, Russell RG, McKenna CE (2007) Synthesis and biological evaluation of α-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate. J Med Chem 50:5967–5975
Takahashi N, Udagawa N, Suda T (2014) Vitamin D endocrine system and osteoclasts. Bonekey Rep 3:1–9
Fleisch HA, Russell RGG, Bisaz S, Mühlbauer RC, Williams DA (1970) The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1:12–18
Grases F, Sanchis P, Perelló J, Isern B, Prieto RM, Fernández-Palomeque C, Torres JJ (2007) Effect of crystallization inhibitors on vascular calcifications induced by vitamin D: A pilot study in Sprague-Dawley rats. Circ J 71:1152–1156
Duan X, Zhou Y, Teng X, Tang C, Qi Y (2009) Endoplasmic reticulum stress-mediated apoptosis is activated in vascular calcification. Biochem Biophys Res Commun 387:694–699
Price PA, Buckley JR, Williamson MK (2001) The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J Nutr 131:2910–2915
Saji F, Shigematsu T, Sakaguchi T, Ohya M, Orita H, Maeda Y, Ooura M, Mima T, Negi S (2010) Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH. Am J Physiol Renal Physiol 299:F1212–F1217
Boskey A (2003) Bone mineral crystal size. Osteoporos Int 14:S16–S21
Neven EG, De Broe ME, D’Haese PC (2009) Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge? Kidney Int 75:580–582
Zhou S, Fang X, Xin H, Guan S (2013) Effects of alendronate on the Notch1-RBP-Jk signaling pathway in the osteogenic differentiation and mineralization of vascular smooth muscle cells. Mol Med Rep 8:89–94
Hu ML, Huang Y, Zheng ZH, Lei Y, Liu RJ, Wang XH, Lindholm B, Yu XQ (2012) Zoledronate inhibits phosphate and bone morphogenic protein 2-induced extracellular calcification of vascular smooth muscle cells in vitro. Exp Ther Med 3:841–844
Masuzaki T, Ayukawa Y, Moriyama Y, Jinno Y, Atsuta I, Ogino Y, Koyano K (2010) The effect of a single remote injection of statin-impregnated poly (lactic-co-glycolic acid) microspheres on osteogenesis around titanium implants in rat tibia. Biomaterials 31:3327–3334
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Dr. Takashi Shigematsu serves as a consultant for Fuji Yakuhin. The manuscript does not contain clinical studies or patient data.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ishida, K., Ashizawa, N., Matsumoto, K. et al. Novel bisphosphonate compound FYB-931 preferentially inhibits aortic calcification in vitamin D3-treated rats. J Bone Miner Metab 37, 796–804 (2019). https://doi.org/10.1007/s00774-019-00987-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00774-019-00987-0